MEDNAX (MD) Tops Q2 EPS by 3c ; Provides Outlook

MEDNAX (NYSE: MD) reported Q2 EPS of $0.63, $0.03 better than the analyst estimate of $0.60. Revenue for the quarter came in at $488 million versus the consensus estimate of $478.49 million.

2026 Outlook

Pediatrix reaffirms its full year 2026 outlook for Adjusted EBITDA, as defined above, and anticipates Adjusted EBITDA will be in a range of $280 million to $300 million.

For earnings history and earnings-related data on MEDNAX (MD) click here.

You May Also Be Interested In

• Aggreko files for proposed IPO
• Macquarie Downgrades Tongcheng Travel Holdings Ltd (780:HK) to Neutral
• UBS Starts Digi Spain Telecom SA (DIGIS:SM) at Buy